(PubMed) Clements M, Heffernan M, Ward M, et al
doi:10.1128/AEM.02173-12
Day one: BPC-157, KPV, TB-500, MOTS-C
Patients are investing in a personalized treatment design, medical oversight, quality sourcing, and support
At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
This safety profile makes it suitable for individuals who cannot tolerate or are contraindicated for growth hormone therapy
